OATH
LIVE

Serial Number

99457431

Owner

Caper Labs, Inc.

Attorney

Isaac M. Fine

Filing Date

Oct 22, 2025

Add to watchlist:

No watchlists yet
View on USPTO

OATH Trademark

Serial Number: 99457431

OATH is a trademark filed by Caper Labs, Inc. on October 22, 2025. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Caper Labs, Inc. (27 trademarks)

1 Letterman Drive, Bldg. C3500
San Francisco, CA 94129

Entity Type: 03

Trademark Details

Filing Date

October 22, 2025

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for alleviating side effects of cancer treatments; Pharmaceutical preparations for alleviating side effects of chemotherapy; Pharmaceutical preparations for alleviating side effects of radiation therapy; Pharmaceutical preparations for alleviating side effects of targeted cancer treatments; Pharmaceutical preparations for alleviating side effects of targeted cancer treatments, namely, tyrosine kinase inhibitors; Pharmaceutical preparations for alleviating side effects of immunotherapy treatments; Pharmaceutical preparations for alleviating gastrointestinal distress, mucocitis, nausea, vomiting and diarrhea; Pharmaceutical preparations for stimulating appetite; Pharmaceutical preparations for preventing weight loss; Pharmaceutical preparations for protecting bone marrow and the production of bone marrow; Pharmaceutical preparations for protecting stem cells and stimulating the production of stem cells; Pharmaceutical preparations for increasing resiliency of stem cells, increasing the number of stem cells, and preventing the reduction of stem cell populations; Pharmaceutical preparations for protecting blood cells, alleviating anemia, neutropenia, thrombocytopenia, and alleviating low blood counts; Pharmaceutical preparations for alleviating dose limiting side effects of cancer treatments, chemotherapy, radiation therapy, targeted cancer treatments and immunotherapy treatments; Pharmaceutical preparations for the prevention and treatment of side effects of cancer treatments; Pharmaceutical preparations for the prevention and treatment of side effects of chemotherapy; Pharmaceutical preparations for the prevention and treatment of side effects of radiation therapy; Pharmaceutical preparations for the prevention and treatment of side effects of targeted cancer treatments; Pharmaceutical preparations for the prevention and treatment of side effects of targeted cancer treatments, namely, tyrosine kinase inhibitors; Pharmaceutical preparations for the prevention and treatment of side effects of immunotherapy treatments; Pharmaceutical preparations for the prevention and treatment of gastrointestinal distress, mucocitis, nausea, vomiting and diarrhea; Pharmaceutical preparations for the prevention and treatment of loss of appetite; Pharmaceutical preparations for the prevention and treatment of weight loss; Pharmaceutical preparations for the treatment and prevention of bone marrow damage; Pharmaceutical preparations for the treatment and prevention of stem cell damage and reduction of stem cell populations; Pharmaceutical preparations for the treatment and prevention of blood cell damage, anemia, and low blood count; Pharmaceutical preparations for the treatment and prevention of dose limiting side effects of cancer treatments, chemotherapy, radiation therapy, targeted cancer treatments and immunotherapy treatments; Pharmaceutical preparations for the treatment and prevention of side effects of cancer treatments, chemotherapy, radiation therapy, targeted cancer treatments and immunotherapy treatments, namely, reduced fertility; Pharmaceutical preparations for supporting stem cell health and production; Pharmaceutical preparations for supporting stem cell health and production, namely for stimulating uterine, bone marrow and gastrointestinal track stem cell production; Pharmaceutical preparations for the treatment of radiation exposure; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of inflammatory bowel disease, ulcerative colitis and other inflammatory bowel disorders; Pharmaceutical preparations for the enhancement of chemotherapy; Pharmaceutical preparations for the enhancement of immunotherapy; Fertility enhancement preparations

Filing History

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Apr 22, 2026 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Apr 22, 2026 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 22, 2026 GNRN
NON-FINAL ACTION E-MAILED
Jan 22, 2026 GNRT
NON-FINAL ACTION WRITTEN
Jan 22, 2026 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Jan 22, 2026 ZZZX
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 22, 2026 CNSA
ASSIGNED TO EXAMINER
Jan 21, 2026 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 12, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 12, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 12, 2025 REAP
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 22, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
Oct 22, 2025 MAFR
NEW APPLICATION ENTERED
Oct 22, 2025 NWAP